GlassScriptPhysician profile
John J Ingram
NPI 1053480996
$3,063.11
in general payments reported to CMS, 2019-2025
24 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $401 · 2021: $726 · 2022: $221 · 2023: $647 · 2024: $173 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $531.34 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $499.81 | 2019-2025 | |
| Amgen INC. | $268.53 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $235.07 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Esperion Therapeutics, INC. | $224.57 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.19 | 2020-2025 | Jardiance |
| Novo Nordisk INC | $147.68 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $146.07 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $121.82 | 2023 | |
| Abbvie INC. | $103.39 | 2022-2023 | |
| Grt US Holding, INC. | $90.00 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $89.56 | 2022 | |
| Amarin Pharma, INC. | $87.47 | 2019 | |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Averitas Pharma INC. | $46.00 | 2023 | Qutenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $43.99 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $33.99 | 2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $28.11 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $27.57 | 2024-2025 | Gardasil 9, Gardasil, Capvaxive |
| Sanofi-Aventis U.S. LLC | $27.46 | 2020 | |
| Impel Pharmaceuticals INC. | $22.53 | 2022 | |
| Genentech USA, INC. | $20.89 | 2020 | |
| Astellas Pharma US INC | $17.06 | 2023 | Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $15.51 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.